AI-Generated Summary
Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$2,000,000.00Target Investment:
$1,000,000.00
Education
- TW
- Uo
- CU
Lists including Michael
Work Experience
General Partner
2024
Board Member
2021
Stealth Biotech
2020
Board Member
2020
Provide strategic, business development, and financing advice to CEO and CSO of UNP, an emerging biotech company that is unlocking the potential of macrocycle drug discovery through data science and massively parallel synthesis.
2020 - 2024
Business Advisor
2020 - 2024
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients. Pipeline projects include HIV, PML/JCV, HSV, and COVID-19 Treatment & Prevention. https://www.Excision.Bio/
2020 - 2024
Board Member
2020 - 2024
Rover Diagnostic’s Lightspeed is a potentially best-in-class, cost-effective, point-of-care, COVID-19 test that is saliva-based, CLIA-waived, and uses the gold-standard rtPCR to deliver results in under 15 minutes. It was accepted in the NIH RADx program to accelerate availability and capacity for COVID testing.
2020 - 2022
SeniorAdvisor
2020 - 2022
Provide corporate strategy, business development, and financing advice to the CEO and CBO of Immunai, an innovate biotech company that is comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.
2017 - 2019
President and CEO
2017 - 2019
2010 - 2017
Senior Vice President, Strategy and Investor Relations
2010 - 2017
2006 - 2010
Biotech Analyst
2006 - 2010
2004 - 2006
Biotech Analyst
2004 - 2006